Biopharmaceutical Production Sites
Boehringer Ingelheim offers the entire production technology chain at its biopharmaceutical manufacturing facilities in Vienna (Austria), Biberach (Germany) and Fremont (USA).
Centres of excellence
-
Boehringer Ingelheim in Biberach, Germany
Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach (Germany), has Europe's largest biopharmaceutical plant for the development and manufacture of therapeutic proteins from mammalian cell cultures. Biberach is a major Fill & Finish site for biopharmaceuticals. Three of the world's best-selling biotechnology products are produced at this site today. The plant received the Industrial Excellence Award 2000 for Best Factory from the INSEAD Management Institute in France and Germany's WHU-Otto Beisheim School of Management.
-
Boehringer Ingelheim Pharma GmbH & Co. KG
Birkendorfer Str. 65
88397 Biberach an der Riss
Germany- Phone +49/7351/540
- Fax +49/7351/54 46 00
- Website
- Your way to us
- Phone +49/7351/540
-
-
Boehringer Ingelheim in Vienna, Austria
Boehringer Ingelheim RCV GmbH & Co KG (Vienna), produces therapeutically active proteins from micro-organisms and yeast with state-of-the-art fermentation technologies. Other areas of production include microbial vaccines, plasmid DNA for gene therapy, protein scaffolds and antibody fragments. One of the top twenty biopharmaceutical blockbusters is manufactured at this plant. The site received the Frost & Sullivan Technoloy Leadership Award and the Customer Value Award 2004 for its provision of superior contract manufacturing services to customers across the globe.
-
Boehringer Ingelheim Fremont, USA
Nestled in the heart of Northern California, the San Francisco Bay Area is home to the largest cluster of life sciences companies in the United States. The Boehringer Ingelheim Fremont facility fits well into this hub of innovation.
Its unique architectural style features extensive use of glass throughout, providing visibility into production suites and symbolizing our unique way of open and transparent collaboration with our customers. The 200,000 square feet state-of-the-art facilities are ideally suited for the development and commercialization of our customer projects like proteins and antibodies for therapeutic use.
With a full set of capabilities in process development, manufacturing and quality, Boehringer Ingelheim Fremont can mitigate the risks for our customers with multiproduct operations for both clinical and commercial production.
